We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Northern Region Judge J M Going and member Mr J Faulkner sitting on 11 January 2021
The Court of Appeal has confirmed that firms broke the law by charging excessive and unfair prices for hydrocortisone tablets over a decade.
The Competition and Markets Authority (CMA) investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
The CMA investigated alleged excessive and unfair pricing with respect to liothyronine tablets under Chapter II CA98.
Southern Region, Judge J Dobson on 08 December 2020
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).